Loading TrenasCycles…
Anabolic-androgenic steroid
test
Testosterone builds muscle and strength and can make muscles look fuller. Some of the extra scale weight is water, not new muscle. Enanthate, cypionate and other esters release the same hormone at different speeds. Main downsides are acne, possible hair loss, higher blood pressure and blood counts, estrogen-related bloating or breast changes, and suppressed natural testosterone and fertility.
Randomized muscle-size and strength trial in 43 healthy men, with and without resistance training. This was supraphysiologic research exposure, not a TRT dose or a recommended cycle.
Controlled trials show dose-dependent gains in fat-free mass and strength at supraphysiologic exposure. Exogenous testosterone also suppresses LH/FSH and sperm production.
Erythrocytosis, acne, infertility/testicular suppression, gynecomastia, blood-pressure and lipid changes; cardiovascular risk rises with nonmedical AAS exposure.
CBC/hematocrit; blood pressure; HDL/LDL/triglycerides; liver enzymes; reproductive hormones/fertility; prostate assessment when clinically appropriate.
Prescription replacement therapy for confirmed testosterone deficiency; supraphysiologic bodybuilding use is not an approved indication.
Other aliases: test · testosterone esters · Sustanon · Sustanon 250 · Testosterone enanthate · Testosterone cypionate · Testosterone propionate
Supraphysiologic testosterone plus training increased fat-free mass, muscle size and strength.
Short trial; not a safety endorsement or dosing guide.
Original source ↗Fat-free mass and strength rose with exposure; hemoglobin and adverse effects also changed.
Controlled medical setting; limited duration.
Original source ↗Exogenous testosterone suppressed LH/FSH and sperm production.
Population and regimen do not represent every user.
Original source ↗Long-term AAS use was associated with myocardial dysfunction and coronary atherosclerosis.
Observational; exposure self-selected.
Original source ↗AAS use was associated with increased cardiovascular-disease outcomes.
Observational; residual confounding possible.
Original source ↗